Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Epidemiology, Vanderbilt University School of Medicine, Nashville, Tennessee.
J Surg Res. 2020 Jan;245:265-272. doi: 10.1016/j.jss.2019.07.059. Epub 2019 Aug 14.
Although insurance and race-based survival disparities in colon cancer are well studied, little is known regarding how these survival disparities are impacted by type of treating facility.
This is a retrospective cohort study of 433,997 patients diagnosed with colon adenocarcinoma using the National Cancer Database (NCDB). Using Cox proportional hazard analyses, we assessed overall survival (OS) as a function of race, insurance status, and treating facility, after adjusting for demographic and clinical factors. We also assessed differences in OS according to race and insurance status stratified by treating facility type.
OS was significantly diminished for blacks (hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.07-1.10; P < 0.001) and increased for patients of other race (primarily Asians; HR, 0.76; 95% CI, 0.74-0.78) compared with whites. Patients with private insurance had improved OS compared with uninsured (HR, 1.28; 95% CI, 1.25-1.31; P < 0.001), Medicaid (HR, 1.35; 95% CI, 1.33-1.38; P < 0.001) and Medicare (HR, 1.13, 95% CI, 1.12-1.15; P < 0.001) patients. Compared with patients treated at comprehensive community programs, patients treated at academic centers (ACs) had improved OS (HR, 0.86; 95% CI, 0.85-0.88; P < 0.001). When stratified by type of treating facility, racial disparities were not mitigated for patients treated at ACs compared with other facilities (P = 0.266 for interaction). At ACs, patients with Medicaid had persistent OS disparities compared with patients with private insurance (HR, 1.12; 95% CI, 1.09-1.15; P < 0.001), although these disparities were significantly diminished compared with patients treated at other facilities (HR, 1.41; 95% CI, 1.38-1.45; P < 0.001).
Other race, private insurance, and treatment at AC were independently associated with improved OS in patients with colon cancer. Medicaid-based, but not race-based, survival disparities are reduced at ACs compared with other facilities.
尽管结肠癌的保险和种族相关的生存差异已得到充分研究,但对于这些生存差异如何受治疗机构类型的影响知之甚少。
这是一项使用国家癌症数据库(NCDB)对 433997 例结肠腺癌患者进行的回顾性队列研究。我们使用 Cox 比例风险分析,在调整了人口统计学和临床因素后,评估了种族、保险状况和治疗机构对总生存(OS)的影响。我们还根据治疗机构类型,按种族和保险状况分层评估了 OS 的差异。
与白人相比,黑人(风险比[HR],1.09;95%置信区间[CI],1.07-1.10;P<0.001)的 OS 明显降低,其他种族(主要是亚洲人)的患者 OS 增加(HR,0.76;95%CI,0.74-0.78)。与未参保者相比,有私人保险的患者 OS 改善(HR,1.28;95%CI,1.25-1.31;P<0.001)、医疗补助(HR,1.35;95%CI,1.33-1.38;P<0.001)和医疗保险(HR,1.13,95%CI,1.12-1.15;P<0.001)患者。与在综合性社区项目中接受治疗的患者相比,在学术中心(AC)接受治疗的患者 OS 改善(HR,0.86;95%CI,0.85-0.88;P<0.001)。按治疗机构类型分层时,与其他机构相比,AC 治疗的患者种族差异没有得到缓解(交互作用 P=0.266)。在 AC 中,与私人保险患者相比,医疗补助患者的 OS 持续存在差异(HR,1.12;95%CI,1.09-1.15;P<0.001),尽管与其他机构相比,这些差异显著缩小(HR,1.41;95%CI,1.38-1.45;P<0.001)。
其他种族、私人保险和在 AC 治疗与结肠癌患者的 OS 改善独立相关。与其他机构相比,在 AC 中,基于医疗补助的而不是基于种族的生存差异减少。